{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:07:43Z","timestamp":1792688863393,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.hoc.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T18:14:12Z","timestamp":1687889652000},"page":"761-776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Investigation and Management of Immunoglobulin M\u2013 and Waldenstr\u00f6m-Associated Peripheral Neuropathies"],"prefix":"10.1016","volume":"37","author":[{"given":"Oliver","family":"Tomkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Viala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.410330514","article-title":"Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein","volume":"33","author":"Tatum","year":"1993","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.007_bib3","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.007_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5","article-title":"Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy","volume":"23","author":"Notermans","year":"2000","journal-title":"Muscle Nerve"},{"issue":"13","key":"10.1016\/j.hoc.2023.04.007_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.007_bib6","first-page":"4955","article-title":"Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy","volume":"269","author":"Bardel","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.04.007_bib7","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1200\/jco.2010.28.15_suppl.8114","article-title":"Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM)","volume":"28","author":"Treon","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.04.007_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136558","article-title":"Neuropathy with IgM gammopathy: incidence, characteristics and management, a rory morrison W.M.U.K registry analysis","volume":"136","author":"Tomkins","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.007_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.1992.tb06033.x","article-title":"Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies","volume":"85","author":"Nobile-Orazio","year":"1992","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","article-title":"Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features","volume":"89","author":"Svahn","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.007_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/jnnp-2012-303013","article-title":"Tremor in inflammatory neuropathies","volume":"84","author":"Saifee","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.007_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/practneurol-2020-002837","article-title":"Paraproteinaemic neuropathy: MGUS and beyond","volume":"21","author":"Carroll","year":"2021","journal-title":"Practical Neurol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/brain\/117.5.941","article-title":"Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside","volume":"117","author":"Kaku","year":"1994","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ana.410180203","article-title":"Immunofluorescence study of patients with neuropathy and IgM M proteins","volume":"18","author":"Takatsu","year":"1985","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.007_bib16","first-page":"383","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung","year":"1991","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","volume":"15","year":"2010","journal-title":"J\u00a0Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ana.410360313","article-title":"Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"36","author":"Nobile-Orazio","year":"1994","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.007_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<55::AID-MUS8>3.0.CO;2-F","article-title":"Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical\/electrophysiological features in 40 cases","volume":"21","author":"Chassande","year":"1998","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF00294374","article-title":"Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients","volume":"79","author":"Vital","year":"1989","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.007_bib21","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.007_bib22","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.hoc.2023.04.007_bib24","doi-asserted-by":"crossref","first-page":"577725","DOI":"10.1016\/j.jneuroim.2021.577725","article-title":"Anti-MAG neuropathy: From biology to clinical management","volume":"361","author":"Steck","year":"2021","journal-title":"J\u00a0Neuroimmunol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.18202","article-title":"Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: a report of 64 patients","volume":"198","author":"Nivet","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib26","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurology - Neuroimmunology Neuroinflammation."},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.007_bib28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.007_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A\u00a0treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib30","first-page":"157","article-title":"The diagnostic utility of determining anti-GM1: GalC complex antibodies in multifocal motor neuropathy: a validation study","volume":"2","author":"Galban-Horcajo","year":"2015","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: controversies and priorities","volume":"91","author":"Yeh","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib32","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"Pt 8","key":"10.1016\/j.hoc.2023.04.007_bib33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","article-title":"Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment","volume":"125","author":"Van den Berg-Vos","year":"2002","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.007_bib34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell\u2013targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"issue":"Pt 10","key":"10.1016\/j.hoc.2023.04.007_bib35","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","article-title":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","volume":"124","author":"Willison","year":"2001","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/mus.24192","article-title":"Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism","volume":"49","author":"Yuki","year":"2014","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.007_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","article-title":"Diagnosis and treatment of chronic acquired demyelinating polyneuropathies","volume":"10","author":"Latov","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MD.0b013e318288925c","article-title":"The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases","volume":"92","author":"Terrier","year":"2013","journal-title":"Medicine"},{"issue":"25","key":"10.1016\/j.hoc.2023.04.007_bib39","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","article-title":"Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"119","author":"Terrier","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13196","article-title":"Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases","volume":"168","author":"Harel","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.007_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.24745","article-title":"Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia","volume":"92","author":"Sidana","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.23608","article-title":"Long-term outcome of monoclonal (type 1) cryoglobulinemia","volume":"89","author":"N\u00e9el","year":"2014","journal-title":"Am J Hematol"},{"issue":"Pt 3","key":"10.1016\/j.hoc.2023.04.007_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/brain\/111.3.541","article-title":"Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases","volume":"111","author":"Nemni","year":"1988","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib44","doi-asserted-by":"crossref","first-page":"103034","DOI":"10.1016\/j.autrev.2022.103034","article-title":"Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature","volume":"21","author":"Pouchelon","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13156","article-title":"Guidelines on the diagnosis and investigation of AL amyloidosis","volume":"168","author":"Gillmore","year":"2015","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2023.04.007_bib46","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/practneurol-2018-002098","article-title":"Diagnosis of amyloid neuropathy","volume":"19","author":"Kapoor","year":"2019","journal-title":"Practical Neurol"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.007_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","article-title":"Heterogeneous spectrum of neuropathies in Waldenstr\u00f6m's macroglobulinemia: a diagnostic strategy to optimize their management","volume":"17","author":"Viala","year":"2012","journal-title":"J\u00a0Peripher Nerv Syst"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1085-9489.2004.09405.x","article-title":"Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies","volume":"9","author":"Vital","year":"2004","journal-title":"J\u00a0Peripher Nerv Syst"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.007_bib50","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/jnnp.2004.057620","article-title":"Clinical spectrum of cryoglobulinaemic neuropathy","volume":"76","author":"Gemignani","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2020.1757423","article-title":"Electrochemical skin conductance values suggest frequent subclinical autonomic involvement in patients with AL amyloidosis","volume":"27","author":"Montcuquet","year":"2020","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.amjmed.2005.08.043","article-title":"Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis","volume":"119","author":"Hazenberg","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia\u2014A British Society for Haematology guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.007_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mus.27045","article-title":"Peripheral nerve neurolymphomatosis: clinical features, treatment, and outcomes","volume":"62","author":"Keddie","year":"2020","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.007_bib56","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1212\/WNL.37.7.1231","article-title":"Demyelinating neuropathy due to primary IgM kappa B cell lymphoma of peripheral nerve","volume":"37","author":"Ince","year":"1987","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.007_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/CND.0000000000000183","article-title":"Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis","volume":"19","author":"Daher","year":"2018","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"24","key":"10.1016\/j.hoc.2023.04.007_bib58","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","article-title":"Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report","volume":"115","author":"Grisariu","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.007_bib59","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.37.9.1506","article-title":"Peripheral neuropathy in macroglobulinemia: Incidence and antigen\u2013specificity of M proteins","volume":"37","author":"Nobile-Orazio","year":"1987","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.2005.071175","article-title":"Peripheral neuropathies in Waldenstr\u00f6m's macroglobulinaemia","volume":"77","author":"Levine","year":"2006","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.007_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.61.1.36","article-title":"Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients","volume":"61","author":"Maisonobe","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J\u00a0Peripher Nerv Syst"},{"issue":"23","key":"10.1016\/j.hoc.2023.04.007_bib63","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.007_bib64","first-page":"e319","article-title":"Diagnostic Yield of FDG-PET\/CT, MRI, and CSF Cytology in Non-Biopsiable Neurolymphomatosis as a Heralding Sign of Recurrent Non-Hodgkin's Lymphoma","volume":"7","author":"Shaikh","year":"2015","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.007_bib65","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3324\/haematol.2019.239632","article-title":"Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls","volume":"105","author":"S\u00e6mundur","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.007_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.16210","article-title":"IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.007_bib67","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","article-title":"High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy","volume":"89","author":"Vos","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.007_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mus.27201","article-title":"Nerve biopsy: Current indications and decision tools","volume":"64","author":"Nathani","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:20:40Z","timestamp":1760185240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889858823000412"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation and Management of Immunoglobulin M\u2013 and Waldenstr\u00f6m-Associated Peripheral Neuropathies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}